Trial Profile
A phase II clinical trial of consolidation treatment with iodine I 131 tositumomab for multiple myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Mar 2024 Planned End Date changed from 1 Mar 2023 to 1 Sep 2024.
- 02 Nov 2022 Planned End Date changed from 1 Jul 2022 to 1 Mar 2023.
- 16 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Jul 2022.